Bionomics IPO Presentation Deck

MOU for BNC210 and MDMA Derivative (EMP-01) for Post-Traumatic Stress Disorder Joint Feasibility Assessment with: Empath Bio O EMP-01 = 3,4-Methylenedioxymethamphetamine (MDMA) derivative Bionomics ATAI LIFE SCIENCES DAILY NEWS Word • Business Finance Lifestyle Travel - Sport - Weather 22 February 2021 Illustrative Memorandum of Understanding with EmpathBio's MDMA Derivative Initial collaborative framework of preclinical studies to collectively explore a combination drug treatment regimen with BNC210 and EMP-01 MDMA-assisted psychotherapy has demonstrated significant symptom improvement in PTSD patients FDA has granted a Breakthrough Therapy designation to MDMA-assisted psychotherapy EmpathBio is developing MDMA derivatives that may permit the entactogenic effects of MDMA to be separated from some of the known adverse effects To explore the possibility of a combination treatment regimen warranting clinical evaluation 25

View entire presentation